Delgocitinib Cream Shows Dose-Dependent Benefits for Atopic Dermatitis

Clinical trials indicate that Delgocitinib cream provides significant, dose-dependent relief for patients suffering from atopic dermatitis.

The topical treatment demonstrated a reduction in inflammation and skin irritation across various patient demographics during the study period.

Researchers are now evaluating the long-term safety profile of the cream to determine its viability as a standard dermatological intervention.